CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial - Seite 6

Nachrichtenquelle: globenewswire
20.10.2020, 12:00  |  842   |  0   |   

Diesen Artikel teilen
Seite 6 von 5
Wertpapier


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial - Seite 6 DSMC recommends CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint DSMC also requests another data review when enrollment reaches 293 patients (75%) to analyze all data, including …

Community

Nachrichten des Autors

Titel
Blockchain Foundry Announces CAD$10 Million Private Placement with Institutional Investors
CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, ...
AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its ...
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
Clean Power Capital Announces Appointment of Former Shell Oil Products US Executive David Bray to ...
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento ...
Niu Technologies Announces Fourth Quarter and Full Year 2020 Financial Results
Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder ...
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for ...
Heineken N.V. announces CFO succession: Laurence Debroux to be succeeded by Harold van den Broek on 1 June 2021
Titel
Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million
Emerging Markets Report: Expand the Brand
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for ...
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results ...
Hunter Technology Market Testing Pilot April Launch
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital ...
Algernon Pharmaceuticals Announces Private Placement
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in ...
Bitfarms Announces Purchase Agreement for 48,000 MicroBT Miners to Expand Hash Rate Capacity by ...
BIGG Digital Assets Inc. Announces Grant of Stock Options
Titel
Spineway Expansion in Asia
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to ...
SPINEWAY: NEW BUSINESS AGREEMENT DEDICATED TO 3D INNOVATION
American Lithium Reaches Agreement to Acquire Plateau Energy Metals and Consolidate ...
REPEAT --TAAT E-Commerce Launching Wednesday February 17, Availing Original, Smooth, and Menthol to ...
Emerging Markets Report: One + One = Three
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
EHang Responds to Deceptive Wolfpack Research Report
Seeking Alpha Blog Post Details Growth of Alternatives to Incumbent CPG Products in February 11 ...
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product ...
Titel
Spineway Expansion in Asia
AgraFlora Organics Expects to Enter Edibles Market in Q1
HyperSolar Changes Company Name to SunHydrogen
Halo Announces Pricing of Overnight Marketed Offering of Units
WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020
Bombardier unterzeichnet Vertrag für weitere zehn Jahre Betrieb und Wartung des automatischen ...
Ocugen and Bharat Biotech to Co-Develop COVAXIN, a Whole-Virion Inactivated COVID-19 Vaccine, for ...
HyperSolar To Begin Production on 100 Hydrogen Generation Units for Demonstration
Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of ...

Nachrichten zu den Werten

ZeitTitel
12:10 Uhr
CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, Monday, March 8
12:05 Uhr
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
12:00 Uhr
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
07.03.21
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
06.03.21
CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil
05.03.21
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
03.03.21
CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement
22.02.21
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients

COMMUNITY

ZeitTitel
17:11 Uhr
26.297
CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5
03.03.21
2
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data fo